Pharmaceutical Science Advances最新文献

{"title":"Phenol and chromone compounds for in silico inhibition of nsP2 and nsP3 of Chikungunya virus","authors":"Joan Petrus Oliveira Lima ,&nbsp;Caio Henrique Alexandre Roberto ,&nbsp;Matheus Nunes da Rocha ,&nbsp;Victor Moreira de Oliveira ,&nbsp;Rafael Melo Freire ,&nbsp;Ralph Santos-Oliveira ,&nbsp;Emmanuel Silva Marinho ,&nbsp;Pedro de Lima Neto ,&nbsp;Pierre Basílio Almeida Fechine","doi":"10.1016/j.pscia.2025.100084","DOIUrl":"10.1016/j.pscia.2025.100084","url":null,"abstract":"<div><div>The rising concern about neglected tropical diseases imposes a global challenge, in this sense, this work brings 12 potential candidates based on chromone and phenol compounds to inhibit nsP2 and nsP3 of the Chikungunya virus (CHIKV), through molecular docking and ADMET evaluation. The molecular docking simulations for the nsP2 showed mild binding, in the nsP3 all the derivatives presented -6 kcal/mol binding affinity and interacts with crucial residues in the replication cycle of CHIKV, the 5 best were chosen as the main derivatives for absorption, distribution, metabolism, excretion and toxicity (ADMET) evaluation). The ADMET results show high drug-likeness values, with good oral and intestinal absorption, excretion, distribution and toxicity, with moderate (Der9 to Der12) and poor (Der8) metabolism. Therefore, the 5 derivatives are potential candidates to treat chikungunya.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"3 ","pages":"Article 100084"},"PeriodicalIF":0.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytochemical analysis and evaluation of the antibacterial and antibiotic potentiation activities of the aqueous extract of Cordia oncocalyx Allemão (Boraginaceae)","authors":"José Thyalisson da Costa Silva ,&nbsp;José Jailson Lima Bezerra ,&nbsp;Talysson Felismino Moura ,&nbsp;Rafael Pereira da Cruz ,&nbsp;Maraiza Gregorio de Oliveira ,&nbsp;Adrielle Rodrigues Costa ,&nbsp;Felicidade Caroline Rodrigues ,&nbsp;João Arthur de Oliveira Borges ,&nbsp;Terezinha Raila Ramos de Sousa ,&nbsp;Maria Flaviana Bezerra Morais-Braga ,&nbsp;Henrique Douglas Melo Coutinho ,&nbsp;José Weverton Almeida-Bezerra","doi":"10.1016/j.pscia.2024.100042","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100042","url":null,"abstract":"<div><p>The global antibiotic resistance crisis highlights the inappropriate use of medicines by the population and the lack of development of new antimicrobial agents. According to various studies, natural products are promising alternatives for combating bacterial resistance and treating infectious diseases. Accordingly, the present study aimed to analyze the chemical composition and evaluate the antibacterial and antibiotic potential of an aqueous extract of <em>Cordia oncocalyx</em> Allemão (AECO). Phytochemical analyses were performed using high-performance liquid chromatography equipped with a diode array detector (HPLC-DAD). The minimum inhibitory concentration (MIC) was used to evaluate the antibacterial activity of <em>C. oncocalyx</em> against conventional and multidrug-resistant (MDR) bacterial strains (<em>Escherichia coli, Pseudomonas aeruginosa</em>, and <em>Staphylococcus aureus</em>). According to HPLC-DAD analysis, the following compounds could be identified in the aqueous extract of <em>C. oncocalyx</em>: luteolin (3.07 ± 0.04 mg/g), caffeic acid (1.05 ± 0.03 mg/g), ellagic acid (0.62 ± 0.05 mg/g), and quercetin (0.58 ± 0.01). AECO did not exhibit antibacterial activity when administered alone (MIC &gt;512 μg/mL). However, when combined with gentamicin, ampicillin, and norfloxacin, AECO potentiated the action of these antibiotics against the multi-resistant strains of <em>P. aeruginosa</em> and <em>S. aureus</em>. Although clinical relevance was not revealed by the <em>in vitro</em> tests against pathogenic bacteria, AECO can combined with commercial antibiotics to improve their antibacterial effects. Future studies focusing on the mechanisms of action of the compounds isolated from <em>C. oncocalyx</em> and toxicological tests are fundamental.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000084/pdfft?md5=3b5fd055b0939ece2db4bd95252fb6b5&pid=1-s2.0-S2773216924000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Grafted tamarind kernel polysaccharide based Al3+ cross-linked hydrogel matrices for sustained release of drug in the gastrointestinal milieu","authors":"Arpita Saha ,&nbsp;Kaushik Mukherjee ,&nbsp;Bijaya Ghosh ,&nbsp;Tapan Kumar Giri","doi":"10.1016/j.pscia.2023.100022","DOIUrl":"10.1016/j.pscia.2023.100022","url":null,"abstract":"<div><p>Ionically cross-linked hydrogel serves as an excellent matrix material for the sustained delivery of drugs. Tablets prepared with tamarind kernel polysaccharide (TKP) as the sole matrix material could not provide sustained release of the incorporated drugs. The purpose of the work was to modify TKP and development of ionically cross-linked hydrogel matrix tablets for sustained drug delivery. Grafting of TKP was performed with methacrylic acid (MAA) following the free radical polymerization technique. Hydrogel matrix tablets using Al³⁺ ion cross-linked grafted TKP were prepared by direct compression method. Al³⁺ ions were found to considerably influence the erosion, swelling, and paracetamol release from the matrix tablet. Retardation of the erosion, swelling, and paracetamol release was observed with increasing the concentration of Al³⁺ ions. The hydrogel matrix tablets showed a slow release of drugs in an acidic medium and a relatively faster drug release in an alkaline medium. The optimized formulation having a co-polymer/aluminium hydroxide (Al(OH)₃) ratio of 1:1, exhibited sustained drug release action for more than 10 h with lower swelling and erosion of the gel matrix. We conclude that Al³⁺ ion cross-linked grafted TKP is an excellent matrix material for sustained delivery of drugs in the gastrointestinal milieu.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100022"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277321692300020X/pdfft?md5=158a22a7bf01c086116cfdf429a46e6a&pid=1-s2.0-S277321692300020X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135965854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted drug conjugates in cancer therapy: Challenges and opportunities","authors":"Geng Jia,&nbsp;Yuqi Jiang,&nbsp;Xiaoyang Li","doi":"10.1016/j.pscia.2024.100048","DOIUrl":"10.1016/j.pscia.2024.100048","url":null,"abstract":"<div><div>Traditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies. Targeted drug conjugates (TDCs) typically comprise targeting ligands, such as specific antibodies, peptides, or small molecules, attached to a cytotoxic agent via a chemical linker. In this study, we briefly discussed the molecular aspects of the key components of TDCs and the mechanisms by which these key factors exert their activity. Moreover, we reviewed FDA-approved TDCs and promising candidates in clinical trials and discussed current challenges and future directions for TDC development, providing insights for the research and development of novel cancer therapeutics using TDCs. TDCs combine the advantages of highly specific targeting and a potent killing effect, enabling accurate and efficient cancer cell elimination. Food and Drug Administration (FDA)-approved antibody-drug conjugates (ADCs) have shown good efficacy in treating various cancers; however, they still present limitations such as immunogenicity, hematotoxicity, and complex pharmacokinetics. Smaller peptide-drug conjugates (PDCs) and small molecule-drug conjugates (SMDCs) may combine the advantages of ADCs while overcoming some of their limitations, thereby presenting more efficacious and safer alternatives. TDCs enhance the therapeutic effects of cytotoxic agents and reduce their adverse effects. However, tumor heterogeneity, limited transmembrane permeability, and drug resistance pose significant challenges for TDCs, potentially affecting their therapeutic efficacy. Nevertheless, TDCs are a promising therapeutic approach for cancer treatment, achieving precise drug delivery while minimizing toxicity and side effects on normal cells.</div></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100048"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277321692400014X/pdfft?md5=846700d9b5859bfcc716e905e2620342&pid=1-s2.0-S277321692400014X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142314135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, synthesis, characterization of ferulic acid and p-coumaric acid amide derivatives as an antibacterial/antioxidant agent","authors":"Chandani G. Halpani,&nbsp;Satyendra Mishra","doi":"10.1016/j.pscia.2023.100023","DOIUrl":"https://doi.org/10.1016/j.pscia.2023.100023","url":null,"abstract":"<div><p>Ferulic acid and <em>p</em>-coumaric acid, cinnamic derivatives of phenolic acid, have antibacterial, prooxidant, and antioxidant effects. In this study ferulic acid and <em>p</em>-coumaric acid amide derivatives were investigated for their antibacterial and antioxidant properties are described in this communication. The most effective conjugates against <em>B subtilis</em> were <strong>5b</strong> (IC₅₀: 215 ​± ​1.3 ​μM) and <strong>4d</strong> (IC₅₀: 336 ​± ​2.7 ​μM) and against <em>P. aeruginosa</em> were <strong>4b</strong> (IC₅₀: 365 ​± ​2.8 ​μM) and <strong>5b</strong> (IC₅₀: 341 ​± ​3.6 ​μM), whereas the none of conjugates were more effective against <em>E. coli</em> than reference Kanamycin. Conjugates <strong>5b</strong> was the most effective against <em>B subtilis</em> of all the synthesized conjugates, with IC₅₀ values of (IC₅₀: 215 ​± ​1.3 ​μM). The free radical scavenging capacity of each compound was determined using the DPPH and ABTS assays. Conjugates <strong>4b</strong> (IC₅₀: 53 ​± ​3.6 ​μM)<strong>, 4c</strong> (IC₅₀: 58 ​± ​1.3 ​μM)<strong>, 4d</strong> (IC₅₀: 57 ​± ​2.5 ​μM), <strong>5b</strong> (IC₅₀: 29 ​± ​1.5 ​μM) and <strong>4a</strong> (IC₅₀: 56 ​± ​4.3 ​μM) have greater antioxidant capacity than ferulic acid and ascorbic acid in the DPPH assay. Whereas in the ABTS assay, compounds <strong>4b (</strong>IC₅₀: 7 ​± ​1.8 ​μM), <strong>5b (</strong>IC₅₀: 5 ​± ​0.7 ​μM), <strong>4a (</strong>IC₅₀: 9 ​± ​3.2 ​μM), <strong>4g (</strong>IC₅₀: 7 ​± ​2.3 ​μM), and <strong>5a (</strong>IC₅₀: 8 ​± ​4.3 ​μM) showed more antioxidant activity than ferulic acid, <em>p</em>-coumaric acid and ascorbic acid. Thus, a large library of compounds derived from bile acid can be easily synthesized for extensive structure-activity relationship studies in order to identify the most appropriate antibacterial and antioxidant agents.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100023"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000211/pdfft?md5=7e8e62c9a09a0b64e96c5bd87a97948f&pid=1-s2.0-S2773216923000211-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92064745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune mechanisms and novel therapies for idiopathic pulmonary fibrosis","authors":"Dongyang Gao ,&nbsp;Wenli Gao ,&nbsp;Zhiguang Zhai ,&nbsp;Wenxiang Zhu","doi":"10.1016/j.pscia.2023.100030","DOIUrl":"10.1016/j.pscia.2023.100030","url":null,"abstract":"<div><p>Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by irreversible lung dysfunction caused by fibroblast proliferation and excessive collagen deposition, is the result of persistent chronic inflammation of the lung parenchyma. Although the pathogenesis is not fully understood, the role of immune mechanisms such as innate immune response, adaptive immunity and immune regulation, and cytokines in the pathophysiological mechanism of pulmonary fibrosis have been gradually recognized. There are currently limited drugs available to treat IPF, and long-term use of these drugs may have many adverse effects. With the elucidation of the underlying immunological pathogenesis, the development of more valuable drugs targeting the immune system becomes possible. This review introduces the immunological pathogenesis of pulmonary fibrosis and the emerging drugs targeting the immune system in recent years, aiming to provide insights into the mechanism and treatment direction of pulmonary fibrosis.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100030"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216923000284/pdfft?md5=ede37c38ed8fc0e930b29c60115f85e3&pid=1-s2.0-S2773216923000284-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139296634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma","authors":"Yawen Yao ,&nbsp;Yue Hu ,&nbsp;Xinwang Meng ,&nbsp;Fenyan Feng ,&nbsp;Feng Xu ,&nbsp;Guangji Wang ,&nbsp;Hua Yu ,&nbsp;Juan Li","doi":"10.1016/j.pscia.2024.100046","DOIUrl":"10.1016/j.pscia.2024.100046","url":null,"abstract":"<div><p>Patients with advanced hepatocellular carcinoma (HCC) are not sensitive to sorafenib (SOR), therefore, combination therapy is required. In this study, an improved thin-film dispersion and post-insertion anchoring technique was utilized to construct a dual-targeted co-delivery SOR and docetaxel (DTX) liposome drug delivery system, folate/chondroitin sulfate with SOR/DTX-modified liposomes (FA/CS@SDLP), to jointly enhance the anti-recurrence and metastasis of HCC. FA/CS@SDLP can establish the gradual release of the two drugs because of successful lysosomal escape in the condensed hyaluronidase environment. The results indicated that modification with folate (FA) and chondroitin sulfate (CS) significantly enhanced the cellular uptake of FA/CS@SDLP and the internalization of SOR/DTX in HepG2 cells through FA and CD44 receptor-mediated endocytosis. Compared to free drugs or the mono-targeted liposomal system (FA@SDLP), FA/CS@SDLP presented higher potency against HepG2 cells regarding pro-apoptosis, anti-proliferation, and anti-metastasis (migration and invasion). Moreover, a more satisfactory antitumor efficacy was observed for FA/CS@SDLP in the pulmonary metastasis of HCC in a mouse model. In summary, dual-targeted co-delivery of liposomes can synergistically treat HCC recurrence and metastasis, providing a new approach for the clinically accurate treatment of HCC.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000126/pdfft?md5=ea9c0c8c42b198b328305e7f15c725ed&pid=1-s2.0-S2773216924000126-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141697484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational design of siRNA-based delivery systems for effective treatment of brain diseases","authors":"Dailin Lu ,&nbsp;Yonghang Sun ,&nbsp;Yuxia Luan,&nbsp;Wenxiu He","doi":"10.1016/j.pscia.2024.100041","DOIUrl":"https://doi.org/10.1016/j.pscia.2024.100041","url":null,"abstract":"<div><p>Effective clinical methods are urgently required to treat brain diseases. Small interfering RNAs (siRNAs) are promising in the treatment of brain diseases because of their ability to target and specifically silence genes associated with disease progression. However, their effectiveness is hindered by physiological barriers such as enzymatic degradation, the blood-brain barrier, and the blood-brain tumor barrier, severely restricting them from reaching the desired target sites. The development of nanotechnology has made the effective delivery of siRNAs to the brain possible. This is accomplished by encapsulating siRNAs in cationic polymers, liposomes, or micelles to improve their stability and targeting efficiency. In this review, we first analyzed the limitations of siRNA delivery in brain diseases such as brain tumors, stroke, and neurodegenerative diseases. Next, we summarized how nanotechnology can offer a solution by enabling effective siRNA delivery to the brain and improving the intracellular transfection efficiency of siRNA. Finally, we discussed the challenges and future advances of siRNA-based delivery systems to facilitate their clinical translation. This review emphasizes the importance of overcoming physiological barriers associated with siRNA delivery and highlights recent advances in the rational design of siRNA-based delivery systems for the effective treatment of brain diseases.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000072/pdfft?md5=8c06ff13b971cd909de39b050bf76bc3&pid=1-s2.0-S2773216924000072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and research progress of oncolytic virus","authors":"Yingyu Chen ,&nbsp;Mengyuan Tao ,&nbsp;Xuwei Wu ,&nbsp;Zheng Tang ,&nbsp;Yinfu Zhu ,&nbsp;Kunxiang Gong ,&nbsp;Yinger Huang ,&nbsp;Wenbo Hao","doi":"10.1016/j.pscia.2024.100037","DOIUrl":"10.1016/j.pscia.2024.100037","url":null,"abstract":"<div><p>Oncolytic viruses (OVs) are natural or genetically recombinant viruses that selectively infect and kill tumor cells without affecting normal cell growth. As a novel type of immunotherapy, OVs have been shown to activate antitumor immune responses, regulate the tumor microenvironment, and enhance the efficacy of immune checkpoint inhibitors. In this review article, we discuss the latest research on the characteristics, antitumor mechanisms, and status of OV research. In terms of mechanism of action, after targeting tumor cells, OVs not only directly lyse tumor cells but also exert antitumor effects through indirect approaches. As an emerging cancer treatment, OVs face challenges that need to be overcome. Finally, we summarize the challenges and prospects for the future application of OVs.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000035/pdfft?md5=d88b2383a920ee72888d00114bd11969&pid=1-s2.0-S2773216924000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140275801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additive manufacturing in nano drug delivery systems","authors":"Md. Habibur Rahman ,&nbsp;Nilufar Yasmin Liza ,&nbsp;Khan Rajib Hossain ,&nbsp;Dipika Ramdas Kalambhe ,&nbsp;Md. Abu Shyeed ,&nbsp;Dilwar Hossain Noor","doi":"10.1016/j.pscia.2024.100036","DOIUrl":"10.1016/j.pscia.2024.100036","url":null,"abstract":"<div><p>The adoption of innovative mixing and fabrication technologies in the pharmaceutical industry has inspired research on nano-drugs and expanded the scope of study in the field. Researchers' interest in the recently discovered drug delivery nanoparticles has increased significantly. This interest is especially seen in the specific preparation of nanoparticles as drug carriers through the use of three-dimensional (3D) printing, a modern additive manufacturing (AM) technology. The benefits of 3D printing, especially at the nanoscale, make it an innovative technology that could revolutionize the pharmaceutical and regenerative medicine industries. The laborious creation of intricate structures made possible by nanoscale 3D printing brings up the possibility of developing nanomedicine and producing functioning tissues and organs. The uses of AM in nano drug delivery systems (NDDS) are highlighted in this study, with a focus on how it can improve drug release kinetics, enhance therapeutic efficacy, and minimize side effects. A new era of personalized medicine has begun with the development of patient-specific formulations made possible by the customization capabilities of 3D printing. This review discusses the various uses of AM in NDDS while addressing issues including scalability, biocompatibility, and regulatory concerns. This review highlights the developing integration between AM and nanotechnology in medicine delivery and discusses ongoing research activities and possible solutions. As this innovative technology develops further, it has the potential to completely change the pharmaceutical development field by providing fresh approaches to the complex problems of contemporary healthcare and advancing the ideas behind drug delivery.</p></div>","PeriodicalId":101012,"journal":{"name":"Pharmaceutical Science Advances","volume":"2 ","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773216924000023/pdfft?md5=cf73c01823eaed30da7a3590cf259c58&pid=1-s2.0-S2773216924000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139966655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}